Skip to main contentWhat happened to Peptide Sciences?
Peptide Sciences, the largest research peptide vendor in the United States by web traffic, voluntarily shut down operations on March 6, 2026. The closure came without advance warning to customers, researchers, or industry partners. The company's website now displays only a brief shutdown notice.
At the time of closure, Peptide Sciences was generating an estimated $7.4 million per month in revenue and receiving approximately 990,000 monthly visits according to third-party traffic analytics. The company had operated for over a decade, building a reputation as one of the most recognized names in the research peptide space. Their catalog included more than 190 research compounds spanning growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity-related peptides.
The abrupt nature of the shutdown caught the research community off guard. No public statement was issued explaining the decision in detail. Ongoing orders were reportedly canceled, and customer service channels went dark within days. Researchers reported receiving no email notification, no timeline for order fulfillment, and no guidance on refund procedures. Social media and research forums saw an immediate spike in posts from confused customers attempting to contact the company through every available channel.
For researchers who had relied on Peptide Sciences as their primary supplier — many for years — the closure created an immediate supply chain disruption that sent ripples across the research peptide market. Academic laboratories with grant-funded projects on fixed timelines were particularly affected, as qualifying a new vendor and validating compound equivalence can take weeks or months.
The timing of the shutdown, coming amid an unprecedented wave of regulatory enforcement against peptide vendors, has led many industry observers to conclude that Peptide Sciences chose to close proactively rather than face potential enforcement action. Understanding the full picture requires examining the regulatory and quality landscape that defined the months leading up to their closure.
Why did Peptide Sciences shut down?
The closure of Peptide Sciences did not happen in a vacuum. It followed a sustained escalation of federal enforcement activity targeting the research peptide and compounding pharmacy industries throughout 2025 and into early 2026. Multiple converging factors created an environment where continued operation carried increasing legal and financial risk.
FDA enforcement escalation. Beginning in September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and related businesses. These letters cited violations ranging from unapproved drug distribution to misbranding and manufacturing deficiencies. The pace and volume of enforcement was unprecedented for the peptide sector. Each warning letter carried the implicit threat of injunctions, seizures, and criminal referrals for non-compliance.
The Amino Asylum warehouse raid. In June 2025, federal agents raided the warehouse operations of Amino Asylum, another prominent research peptide vendor. The raid signaled a shift from warning letters to direct physical enforcement. For vendors across the industry, the raid demonstrated that the FDA was willing to deploy its most aggressive tools against peptide suppliers. This event is widely viewed as a turning point that prompted several vendors to reevaluate their risk exposure.
Resolution of the semaglutide shortage. In February 2025, the FDA officially resolved the semaglutide drug shortage. This resolution eliminated the legal loophole that had allowed compounding pharmacies — and by extension, some research peptide vendors — to produce and sell semaglutide analogs and GLP-1 compounds under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. With the shortage resolved, continued sale of these compounds became significantly riskier from a regulatory standpoint. Given the enormous revenue that GLP-1-related compounds generated for vendors, the loss of this market segment likely factored into financial calculations.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded authority for the FDA to pursue enforcement actions against entities distributing unapproved peptide products. While the legislation had not yet passed at the time of Peptide Sciences' closure, its introduction signaled bipartisan Congressional support for tighter regulation of the peptide market.
Quality failures and third-party testing. Independent analyses published by Finnrick Analytics and other third-party testing services exposed quality concerns across multiple vendors, including Peptide Sciences. Reports documented retatrutide counterfeits circulating in the market and poor purity scores for CJC-1295 from several suppliers. These findings undermined the quality assurances that vendors had marketed to researchers and created additional reputational and legal exposure. When third-party testing reveals that products do not meet advertised specifications, it compounds regulatory risk by providing evidence of potential misbranding.
Taken together, these factors created what many industry analysts describe as an untenable operating environment. Rather than wait for a warning letter, inspection, or raid, Peptide Sciences appears to have made the calculation that voluntary closure was preferable to the alternatives.
What does this mean for the research peptide market?
The closure of Peptide Sciences removed the single largest vendor from the research peptide market virtually overnight. The approximately 990,000 monthly visits that Peptide Sciences received represent a massive population of researchers, academic institutions, and independent investigators who now need alternative suppliers. The downstream effects are reshaping the market in several significant ways.
Immediate supply disruption. Researchers with active projects faced abrupt supply chain failures. Those in the middle of longitudinal studies or multi-phase research protocols were forced to either pause their work or rapidly qualify new suppliers. Switching vendors mid-study introduces variables around compound purity, synthesis methodology, and batch consistency that can compromise data integrity. For research institutions that had procurement agreements or standing orders with Peptide Sciences, the closure also triggered administrative processes to identify, vet, and onboard replacement vendors through institutional purchasing systems — a process that can take weeks even under ideal circumstances.
Heightened quality concerns. Ironically, the closure has intensified scrutiny of supplier quality rather than diminishing it. The third-party testing data that contributed to Peptide Sciences' risk calculus is now being applied more broadly. Researchers are asking harder questions about purity verification, analytical methodology, and whether certificates of analysis represent genuine independent testing. The Finnrick Analytics findings on retatrutide counterfeits and substandard CJC-1295 batches have made the research community more skeptical of vendor claims generally.
Regulatory momentum. The regulatory environment continues to tighten. RFK Jr. has publicly announced plans for peptide reclassification that could fundamentally alter how research compounds are categorized, sold, and regulated. Whether these plans materialize into formal policy remains uncertain, but the direction of travel is clear: the era of minimal oversight for research peptide vendors is ending. Remaining vendors face increased scrutiny from the FDA, state regulators, and an increasingly informed customer base.
Market consolidation. With the largest vendor gone, the remaining players in the market are absorbing displaced demand. This creates both opportunity and risk. Vendors without adequate quality systems, supply chain infrastructure, or compliance practices may struggle under increased volume. Those with robust operations and documented quality standards are positioned to serve researchers who now prioritize reliability and analytical verification over brand familiarity.
The research peptide market is not disappearing. The underlying demand for high-purity research compounds from academic institutions, independent researchers, and scientific organizations remains strong. What is changing is the standard of quality, transparency, and compliance that researchers expect from their suppliers.
What should researchers look for in a peptide supplier in 2026?
In the post-Peptide Sciences landscape, researchers evaluating alternative suppliers should apply rigorous criteria before placing orders. The quality failures documented across the industry make due diligence more important than ever. The following standards represent the minimum threshold for a credible research peptide vendor in the current regulatory environment.
Third-party Certificate of Analysis with every order. A legitimate COA should accompany every batch, not be available only upon request. The COA must be batch-specific — generic COAs that are reused across batches are a red flag. Review the COA for specific batch numbers, testing dates, analyst information, and testing laboratory identification. For a detailed guide on evaluating analytical documentation, see How to Read a Certificate of Analysis.
HPLC verification and mass spectrometry. High-Performance Liquid Chromatography remains the gold standard for purity quantification, while mass spectrometry provides identity confirmation. Suppliers should provide both analytical methods for every compound. Request the actual chromatogram images, not just numerical purity percentages. A deeper discussion of these analytical methods and why they matter is available in our article on Peptide Purity.
Endotoxin testing. Bacterial endotoxin contamination is a critical quality parameter for research compounds used in cell culture, in vitro assays, and other laboratory applications. Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays detect endotoxin contamination. Suppliers who skip this step are cutting corners on fundamental quality assurance.
Cold-chain shipping. Peptides are temperature-sensitive molecules that undergo degradation through oxidation, aggregation, and deamidation when exposed to elevated temperatures during transit. A compound that leaves the warehouse at 99% purity can arrive significantly degraded if shipped without thermal protection, particularly during summer months or to warmer climates. Suppliers should ship with insulated packaging and cold packs as standard practice — not as a premium add-on. Ask prospective vendors whether cold-chain shipping is included or requires an additional fee, and whether they monitor package temperatures during transit.
Transparent purity data. Research-grade compounds should meet a minimum purity threshold of 98%, with premium research applications requiring 99% or higher. Suppliers should publish their purity standards and provide compound-specific analytical data rather than blanket marketing claims. Be wary of vendors who advertise purity percentages on product pages but cannot produce the underlying chromatographic evidence to support those numbers. Transparency means making actual test data available, not just stating a number.
US-based operations. Domestic operations provide accountability, faster shipping, and clearer regulatory jurisdiction. While international suppliers can produce quality compounds, US-based operations simplify dispute resolution, returns, and quality complaints. They also face direct FDA oversight, which — while a constraint — provides a layer of quality assurance for researchers.
These criteria are not aspirational. They represent the baseline for responsible research compound sourcing in an era where the consequences of quality failures extend beyond wasted experiments to potential regulatory exposure for the researchers and institutions involved.
How is Onward Aminos different?
Onward Aminos was built to meet the quality and transparency standards that the research community increasingly demands. Rather than positioning as a replacement for any specific vendor, Onward Aminos operates on a quality framework designed to address the documented failures and gaps that have characterized the broader market. All compounds are intended solely for research purposes.
Onward Aminos maintains a catalog of 64 research-grade compounds, each held to a minimum purity standard of 99% or higher as verified by independent third-party analytical testing. Every order ships with a batch-specific Certificate of Analysis documenting HPLC purity quantification and mass spectrometry identity confirmation. This is not optional documentation — it is included with every shipment as standard practice.
Endotoxin testing is performed on all compounds using validated detection methods. This is a quality step that many vendors skip entirely or perform only on select products. For researchers conducting cell-based assays or sensitive experimental protocols, endotoxin data is not a luxury — it is a necessity.
All shipments are cold-chain packaged as standard, not as an upgrade. Insulated containers with temperature-maintaining materials protect compound integrity from warehouse to laboratory. This matters because a 99% pure compound that arrives degraded due to heat exposure during transit is no longer a 99% pure compound.
Onward Aminos operates entirely within the United States, with domestic warehousing, customer service, and quality oversight. Researchers can browse our full catalog to review available compounds, pricing, and category organization.
The approach is straightforward: provide independently verified, high-purity research compounds with complete analytical documentation and proper handling at every step of the supply chain. In a market where trust has been eroded by quality failures and abrupt closures, the response is not marketing — it is documentation.
What products did Peptide Sciences carry?
Peptide Sciences maintained one of the largest research peptide catalogs in the industry, with over 190 SKUs spanning multiple research categories. Their inventory covered growth hormone secretagogues, metabolic research peptides, tissue repair and healing factors, cognitive and neuroprotective compounds, longevity and anti-aging research peptides, antimicrobial peptides, and cosmetic research compounds.
Their growth hormone secretagogue category included compounds such as ipamorelin, CJC-1295 (both DAC and no-DAC variants), sermorelin, hexarelin, GHRP-2, and GHRP-6. Metabolic research peptides included GLP-1 receptor agonists, tirzepatide, semaglutide, and related compounds that were central to their revenue before the semaglutide shortage resolution. Tissue repair research compounds included BPC-157, TB-500, and related healing factors used extensively in musculoskeletal and wound repair research models. Longevity research peptides included epitalon, GHK-Cu, and NAD+ precursors. Cognitive research compounds spanned several nootropic peptide categories including selank and semax variants.
Onward Aminos covers many of these same research categories with a curated catalog focused on quality over breadth. Researchers who previously sourced from Peptide Sciences will find overlapping compounds including BPC-157, TB500, GHK-Cu, Ipamorelin, GLP-1, Sermorelin Acetate, CJC-1295 NO DAC, Epitalon, and NAD+. The full catalog is available at Browse all compounds.
While Onward Aminos does not attempt to replicate the full breadth of Peptide Sciences' 190+ SKU catalog, the focus on 64 compounds allows for deeper quality control investment per compound — including independent third-party testing, endotoxin screening, and cold-chain logistics for every product rather than only select items.
Is Peptide Sciences coming back?
There is no indication that Peptide Sciences plans to resume operations. The company's domain remains active but serves only a static shutdown message with no timeline for reopening, no contact information for future updates, and no indication that the closure is temporary.
Given the regulatory environment that prompted the closure — including ongoing FDA enforcement actions, proposed legislation expanding agency authority, and the resolution of drug shortage loopholes that previously provided legal cover for certain compound categories — the conditions that would need to change for Peptide Sciences to reopen do not appear imminent. The SAFE Drugs Act continues to advance through legislative channels, and FDA enforcement activity has not slowed since the closure.
Researchers should plan for permanent alternatives rather than waiting for a reopening that may never materialize. This means qualifying new suppliers now, validating compound quality through independent testing, and establishing backup supply relationships to prevent future single-point-of-failure disruptions.
The broader lesson from the Peptide Sciences closure extends beyond any single vendor. Research supply chains built around a single source — regardless of how established that source may appear — carry inherent risk. The fact that a company generating $7.4 million per month in revenue could disappear overnight with no warning illustrates the fragility of vendor relationships in an industry undergoing rapid regulatory transformation.
Diversifying suppliers, maintaining rigorous quality verification practices, and staying informed about regulatory developments are the most effective strategies for ensuring uninterrupted access to the research compounds that scientific work depends on. Researchers should also maintain their own records of COAs, batch numbers, and analytical data from every order, independent of any single vendor's systems, so that research continuity is preserved regardless of vendor status changes.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Onward Aminos does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.